Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK clinical programs — 493 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
493
Drugs
98
Patents
837
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Regeneron UK projects

493 ClinicalTrials.gov programs sponsored by Regeneron UK.

Regeneron UK has 493 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

493 programs

Clinical programs

Page 1 of 11

  1. 13406

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  2. 14130

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  3. 15161

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  4. 2-mg Intravitreous Aflibercept Injection

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  5. 2.0 mg intravitreal aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  6. 22153

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  7. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  8. Aflibercept

    Regeneron UK Limited

    Prostatic Neoplasms

    phase 3 small molecule completed

    1 trial

  9. Aflibercept

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule completed

    3 trials

  10. Aflibercept (EYLEA, BAY86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  11. Aflibercept (Eylea, BAY 86-5321)

    Regeneron UK Limited

    Glaucoma, Neovascular

    phase 3 small molecule completed

    1 trial

  12. Aflibercept 8 mg

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  13. Aflibercept AVE0005

    Regeneron UK Limited

    Colorectal Cancer Metastatic

    phase 3 small molecule terminated

    2 trials

  14. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  15. Alirocumab

    Regeneron UK Limited

    Coronary Vessel

    phase 3 small molecule completed

    1 trial

  16. Alirocumab

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  17. Alirocumab

    Regeneron UK Limited

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  18. Alirocumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule active

    18 trials

  19. Alirocumab

    Regeneron UK Limited

    Type2 Diabetes

    phase 3 small molecule completed

    1 trial

  20. Alirocumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  21. Alirocumab 150 MG/ML [Praluent]

    Regeneron UK Limited

    Hemodialysis

    phase 3 small molecule active

    1 trial

  22. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

  23. Atorvastatin

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  24. CMP-001

    Regeneron UK Limited

    Melanoma

    phase 3 small molecule completed

    3 trials

  25. Cemdisiran

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule terminated

    1 trial

  26. Cemiplimab

    Regeneron UK Limited

    Recurrent Lung Non-Small Cell Carcinoma

    phase 3 mab active

    1 trial

  27. Cemiplimab

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma

    phase 3 small molecule active

    7 trials

  28. Cemiplimab

    Regeneron UK Limited

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  29. Cemiplimab

    Regeneron UK Limited

    Squamous Cell Carcinoma (SCC)

    phase 3 small molecule completed

    1 trial

  30. Dupilumab

    Regeneron UK Limited

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule active

    2 trials

  31. Dupilumab

    Regeneron UK Limited

    Wheezing

    phase 3 small molecule active

    1 trial

  32. Dupilumab

    Regeneron UK Limited

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  33. Dupilumab

    Regeneron UK Limited

    Lichen Simplex Chronicus

    phase 3 small molecule active

    2 trials

  34. Dupilumab Prefilled Syringe

    Regeneron UK Limited

    Asthma Control

    phase 3 small molecule active

    1 trial

  35. Dupilumab SAR231893

    Regeneron UK Limited

    Neurodermatitis

    phase 3 small molecule completed

    2 trials

  36. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  37. Dupilumab SAR231893

    Regeneron UK Limited

    Allergic Fungal Rhinosinusitis

    phase 3 small molecule completed

    1 trial

  38. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis Without Nasal Polyps

    phase 3 small molecule completed

    1 trial

  39. Dupilumab SAR231893

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    1 trial

  40. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  41. Dupilumab SAR231893

    Regeneron UK Limited

    Cold Urticaria

    phase 3 small molecule completed

    1 trial

  42. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

    phase 3 small molecule completed

    2 trials

  43. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    2 trials

  44. EFC10261

    Regeneron UK Limited

    Carcinoma

    phase 3 small molecule completed

    1 trial

  45. EFC10547

    Regeneron UK Limited

    Pancreatic Neoplasm

    phase 3 small molecule terminated

    1 trial

  46. EFC6125

    Regeneron UK Limited

    Ovarian Neoplasms

    phase 3 small molecule completed

    2 trials

  47. Eylea (Aflibercept, BAY86-5321)

    Regeneron UK Limited

    Retinopathy of Prematurity (ROP)

    phase 3 small molecule completed

    2 trials

  48. Fasinumab

    Regeneron UK Limited

    Chronic Low Back Pain

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Regeneron UK have?

493 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.